Trial · NCT03312257
Bifocal & Atropine in Myopia (BAM) Study
NCT03312257, Not applicable, Completed, Jenny Jones; results first posted 2022-12-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bifocal & Atropine in Myopia (BAM) Study. Trials, record NCT03312257. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03312257
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bifocal & Atropine in Myopia (BAM) Study
- NCT number
- NCT03312257
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 49 participants, actual
- Lead sponsor
- Jenny Jones
- Conditions
- Refractive Errors
- Interventions
- Multifocal D +2.50 add & 0.01% atropine
- First posted
- 2017-10-17
- Last updated
- 2022-12-09
- Results first posted
- 2022-12-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Refractive Error Progression | 3 years | Refractive error, as measured by cycloplegic autorefraction in both eyes, will be measured yearly to assess the difference in progression between the combination treatment (+2.50 D add soft bifocal lens and 0.01% atropine) group and the historical control group (+2.50 D add soft bifocal lens only) in the BLINK Study. |
| Secondary | Axial Length Progression | 3 years | Axial length progression, as measured by Lenstar in both eyes, will be measured yearly to assess the difference in progression between the combination treatment (+2.50 D add soft bifocal lens and 0.01% atropine) group and the historical control group (+2.50 D add soft bifocal lens only) in the BLINK Study. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Refractive Error Progression | 3 years | Diopter | MEAN | |
| SECONDARY | Axial Length Progression | 3 years | mm | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Refractive Error Progression | Multifocal D +2.50 Add & 0.01% Atropine | -3.50 | Standard Deviation 0.72 | Diopter | |
| Axial Length Progression | Multifocal D +2.50 Add & 0.01% Atropine | 22 | Standard Error 0.75 | mm |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Multifocal D +2.50 Add & 0.01% Atropine | 49 | |
| Overall Study | COMPLETED | Multifocal D +2.50 Add & 0.01% Atropine | 46 | |
| Overall Study | NOT COMPLETED | Multifocal D +2.50 Add & 0.01% Atropine | 3 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Mild eye itching at the drops administering site, which resolved within a few minutes per subjects. | Eye disorders | Multifocal D +2.50 Add & 0.01% Atropine | 46 | 46 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Multifocal D +2.50 Add & 0.01% Atropine | 0 | 46 |
| Total, other adverse events | Multifocal D +2.50 Add & 0.01% Atropine | 46 | 46 |
| Total, serious adverse events | Multifocal D +2.50 Add & 0.01% Atropine | 0 | 46 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23EY025273 | Myopia Control in Children with Low-Dose Atropine and Soft Bifocal Contact Lenses | HUANG, JUAN | UNIVERSITY OF ALABAMA AT BIRMINGHAM | NATIONAL EYE INSTITUTE | 2015 to 2019 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03312257
GET https://conductscience.org/api/trials/v1/NCT03312257/registered